Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06679634Phase 2Recruiting

Retinoblastoma Phase II Expanded Access Clinical Trial

Role: lead

NCT04005430Phase 1Unknown

A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema

Role: lead

NCT04120636Phase 1Unknown

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Role: lead

NCT04120311Phase 1Unknown

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Role: lead

NCT04156347Phase 1Unknown

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Role: lead

All 5 trials loaded